10-day vs 5-day decitabine: equivalence cannot be concluded
Lancet Haematol
.
2019 Apr;6(4):e177.
doi: 10.1016/S2352-3026(19)30024-9.
Authors
Gerwin Huls
1
,
Stefan Suciu
2
,
Pierre Wijermans
3
,
Michal Kicinski
2
,
Michael Lübbert
4
Affiliations
1
Department of Hematology, University Medical Center Groningen, Groningen 9713, Netherlands. Electronic address: g.huls@umcg.nl.
2
Statistical Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
3
Department of Hematology, Haga Hospital, The Hague, Netherlands.
4
Department of Hematology, Freiburg University Hospital, Freiburg, Germany.
PMID:
30926076
DOI:
10.1016/S2352-3026(19)30024-9
No abstract available
Publication types
Letter
Comment
MeSH terms
Aged
Azacitidine
Decitabine*
Humans
Leukemia, Myeloid, Acute*
Substances
Decitabine
Azacitidine